

## CURRICULUM VITAE

**Name:** Joel Gever

**Position:** Research Scientist II  
Biochemical Pharmacology  
Roche Pharmaceuticals

**Address:** 3431 Hillview Avenue  
Palo Alto, CA 94022

Voice: (650) 855-5167  
Mobile: (650) 804-8294  
Email: joel.gever@roche.com

### EDUCATION:

1991	University of California, Davis, CA	B.S.	Env.Toxicology
1993	University of California, Davis, CA	M.S.	Agr. & Env. Chem.
2009	University College London, U.K.	Ph.D.	Neuroscience

### PRINCIPAL POSITIONS HELD:

1994-95	Syntex	Research Associate I	Bioanalysis/Metabolism
1995-2000	Roche	Research Associate I – III	Genitourinary Research
2001-02	Roche	Research Scientist I	Genitourinary Research
2003-now	Roche	Research Scientist II	Biochemical Pharmacology

### PROFESSIONAL ACTIVITIES

Scientist with 14 years experience at a major pharmaceutical company, with particular expertise in *in vitro* pharmacology

- Lead biologist for P2X3 antagonist program overseeing screening, mechanistic *in vitro* pharmacology experiments and examination of drug candidates in preclinical animal models of pain and bladder function.
- Lead *in vitro* pharmacologist for several programs at all levels of advancement from early lead identification to the later stages of lead optimization.
- Member of clinical team guiding the progression of an advanced molecule through human clinical trials. Sole preclinical pharmacologist on team providing scientific input and guidance as well as informing the team on relevant preclinical research.
- Extensive experience communicating experimental results and scientific interpretation in oral and written form.

- Member of Biochemical Pharmacology Leadership Team. Responsible with other senior scientists for organizational and scientific management of the department. Organized pharmacology tutorials to increase expertise of research associates.
- Managed scientific collaboration with academic group at University College London, guiding research of external scientists and reporting results to the program team.
- Responsible for significant increases in lab productivity through the aggressive application of lab automation and higher throughput assay formats (e.g. HTRF cytokine assays).
- Directly supervised work of four research associates, supporting four or more different programs simultaneously.
- Set up and operated first FLIPR HTS lab at Roche. Devised an assembly line-style design for the lab resulting in the most productive FLIPR lab in the industry.

### **INVITED PRESENTATIONS**

“Applications of academic pharmacology to drug discovery”, Western Pharmacology Society, Honolulu, HI, 2004

“P2X receptors as targets for urology and pain”, IBC Assays and Cellular Targets, Bellevue, WA, 2005

“P2X receptors as targets for urology and pain”, Gordon Conference, Ligand Recognition and Molecular Gating, Ventura, CA, 2008

Undergraduate Pharmacology Symposium, University of California, Santa Barbara, CA, 2008

### **RESEARCH AND CREATIVE ACTIVITIES**

#### **PEER REVIEWED PUBLICATIONS:**

Pharmacological pleiotropism of the human recombinant alpha 1A-adrenoceptor classification. Ford, A.P.D.W., Daniels, D.V., Chang, D.J., **Gever, J.R.**, Jasper, J.R., Lesnick, J.D., Clarke, D.E. *Br. J. Pharmacol.* (1997) 121:6, 1127-35

Human cloned alpha 1A-adrenoceptor isoforms display alpha 1L-adrenoceptor pharmacology in functional studies. Daniels, D.V., **Gever, J.R.**, Jasper, J.R., Kava, M.S., Lesnick, J.D., Meloy, T.D., Stepan, G., Williams, T.J., Clarke, D.E., Chang, D.J., Ford, A.P.D.W. *Eur. J. Pharmacol.* (1999) 370:3, 337-43

In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha 1A-adrenoceptor selective antagonists. Williams, T.J., Blue, D.R., Daniels, D.V., Davis, B., Elworthy, T., **Gever, J.R.**, Kava, M.S., Morgans, D., Padilla, F., Tassa, S., Vimont, R.L., Chapple, C.R., Chess-Williams, R., Eglon, R.M., Clarke, D.E., Ford, A.P.D.W. *Br. J. Pharmacol.* (1999) 127:1, 252-8

Regulated expression of the rat recombinant P2X(3) receptor in stably transfected CHO-K1 tTA cells. Lachnit, W.G., Oglesby, I.B., **Gever, J.R.**, Gever, M., Huang, C., Li, X.C., Jin, H., McGivern, J.G., Ford, A.P.D.W. *J. Auton. Nerv. Syst.* (2000) 81:1-3, 75-81

Pharmacological characteristics of Ro 115-1240, a selective alpha 1A/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence. Blue, D.R., Daniels, D.V., **Gever, J.R.**, Jett, M.F., O'Yang, C., Tang, H.M., Williams, T.J., Ford, A.P.D.W. *BJU Int.* (2004) 93:1, 162-70

Antagonism of ATP responses at P2X receptor subtypes by the pH indicator, dye, Phenol red. King, B.F., Liu, M. Townsend-Nicholson, A., Pfister, J., Ford, A.P.D.W., **Gever, J.R.**, Oglesby, I.B., Schorge, S., Burnstock, G. *Br. J. Pharmacol.* (2005) 145:3, 313-22

Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist. Jaime-Figueroa, S., Greenhouse, R., Padilla, F., Dillon, M.P., **Gever, J.R.**, Ford, A.P.D.W. *Bioorg. Med. Chem. Lett.* (2005) 155:13, 3292-5

Developmental changes in heteromeric P2X(2/3) receptor expression in rat sympathetic ganglion neurons. Dunn, P.M., **Gever, J.R.** Ruan, H.Z., Burnstock, G. *Dev. Dyn.* (2005) 234:3, 505-11

RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Bley, K.R., Bhattacharya, A., Daniels, D.V., **Gever, J.R.**, Jahangir, A., O'Yang, C., Smith, S., Srinivasan, D., Ford, A.P.D.W., Jett, M.F. *Br. J. Pharmacol.* (2006) 147:3, 335-45

Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Ford, A.P.D.W., **Gever, J.R.**, Nunn, P.A., Zhong, Y., Cefalu, J.S., Dillon, M.P., Cockayne, D.A. *Br. J. Pharmacol.* (2006) 147:Supplement 2, S132-43

Pharmacology of P2X channels. **Gever, J.R.**, Cockayne, D.A., Dillon, M.P., Burnstock, G., Ford, A.P.D.W. *Pflugers Arch.* (2006) 452:5, 513-37

Expression and function of rat urothelial P2Y receptors. Chopra, B., **Gever, J.R.**, Barrick, S.R., Hanna-Mitchell, A.T., Beckel, J.M., Ford, A.P.D.W., Birder, L.A. *Am. J. Physiol. Renal Physiol.* (2008) 294:4, F821-9

*In vitro* characterization of RO-4, a novel, orally bioavailable P2X<sub>3</sub>/P2X<sub>2/3</sub> antagonist. **Gever, J.R.**, Soto, R., Henningsen, R., Martin, R., Hackos, D., Milla, M.E., Oglesby, I.B., Dillon, M.P., Burnstock, G., Ford, A.P.D.W. *Br. J. Pharmacol.* (Manuscript accepted, June, 2009)

Pharmacological characteristics of RO-1, a selective P2X<sub>1</sub> antagonist. **Gever, J.R.**, Jaime-Figueroa, S., Knight, G.E., Dunn, P.M. Mandel, D.A., Hegde, S.S., Greenhouse, R.J., Padilla, F., Dillon, M.P., Burnstock, G., Ford, A.P.D.W. (Manuscript in preparation)

Functional expression of P2X and TRPV1 channels during the differentiation of an immortalized human dorsal root ganglion cell line (HD10.6) **Gever, J.R.**, Smith, J., Burnstock, G., Ford, A.P.D.W. (Manuscript in preparation)

### **MEETING ABSTRACTS**

“Differentiation and evoked changes in  $[Ca^{2+}]_i$  signals in an immortalized human dorsal root ganglion cell line” Purines, Madrid, Spain 2000

“The effect of PLURIGEN CM on the proliferation of a clonal human dorsal root ganglion cell line (HD10.6)”, Experimental Biology, San Diego, CA 2003

“In vitro and in vivo characterization of RO0437626, a novel and selective P2X1 antagonist”, Purines, Chapel Hill, NC, 2004

“Characterization of cultured rat urothelial P2Y receptors”, Neuroscience, San Diego, CA, 2004

### **TEACHING AND MENTORING ACTIVITIES**

#### **SUPERVISION OF UNDERGRADUATE STUDIES**

Mentored and supervised the activities of two undergraduate students from the Department of Pharmacology, University of British Columbia. Activities included guidance of research, evaluation of academic written reports and instruction of theoretical and practical aspects of pharmacological research.

May, 2002 – April, 2003      Nicole Baur      University of British Columbia

May, 2001 – April, 2002      Vicky Chan      University of British Columbia

#### **LECTURES AND TUTORIALS**

“P2X Receptors as Targets for Urology and Pain”, Undergraduate Pharmacology Symposium, University of California, Santa Barbara, CA, 2008

“Ion Channels”, Roche Pharmacology Symposium, Roche Palo Alto, CA, 2006

Pharmacology and Receptor Theory Tutorial, Roche Palo Alto, 2004 – 2007

- Planned and delivered a series of tutorials on the basic principles of receptor theory and pharmacology to research colleagues
- Took primary responsibility for the mentoring and continuing education for junior researchers in the Department of Biochemical Pharmacology